Phlox Therapeutics
Margien Boels is an experienced healthcare professional currently serving as the Chief Operating Officer at Phlox Therapeutics, overseeing operations to develop RNA-based therapeutics for genetic cardiomyopathies since March 2022. In addition, Margien holds the position of Senior Impact Officer at the Dutch CardioVascular Alliance, focusing on commercialization and the transformation of research into scalable biomedical solutions. Previous roles include Medical Affairs Manager at Nutricia, where Margien built medical strategies and networks, and Medical Affairs Professional at Eli Lilly and Company, contributing to the diabetes portfolio. Margien earned a PhD from Leiden University Medical Center, where research centered on the visualization of the glycocalyx in kidney blood vessels. Education includes an Executive MBA from Quantic School of Business and Technology, a Master’s in Human Nutrition from the University of Aberdeen, and an MSc in Nutrition and Health from Wageningen University & Research.
This person is not in any teams
Phlox Therapeutics
Phlox Therapeutics pioneers gene therapy to alleviate and cure cardiomyopathies. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short by leveraging RNA-based strategies to reduce the negative effects caused by genetic mutations.